Resona Asset Management Co. Ltd. Grows Stock Position in Kenvue Inc. $KVUE

Resona Asset Management Co. Ltd. increased its stake in Kenvue Inc. (NYSE:KVUE) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 743,508 shares of the company’s stock after buying an additional 26,435 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Kenvue were worth $15,552,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. Stratos Wealth Partners LTD. raised its stake in shares of Kenvue by 10.4% in the first quarter. Stratos Wealth Partners LTD. now owns 14,857 shares of the company’s stock valued at $356,000 after acquiring an additional 1,396 shares during the period. M&T Bank Corp boosted its stake in shares of Kenvue by 11.9% during the 1st quarter. M&T Bank Corp now owns 118,131 shares of the company’s stock worth $2,832,000 after purchasing an additional 12,584 shares during the period. Greenleaf Trust bought a new position in Kenvue during the 1st quarter valued at about $359,000. Country Club Bank raised its position in Kenvue by 1.2% in the 1st quarter. Country Club Bank now owns 247,965 shares of the company’s stock worth $5,877,000 after purchasing an additional 2,872 shares during the period. Finally, Xponance Inc. lifted its stake in Kenvue by 2.3% in the first quarter. Xponance Inc. now owns 267,152 shares of the company’s stock worth $6,406,000 after purchasing an additional 5,949 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 2.6%

KVUE opened at $16.90 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $16.76 and its two-hundred day moving average is $20.30. The company has a market capitalization of $32.37 billion, a P/E ratio of 22.53, a PEG ratio of 2.40 and a beta of 0.71. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.9%. The ex-dividend date is Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on KVUE shares. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. UBS Group dropped their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $15.00 price objective (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Finally, Evercore ISI set a $18.00 target price on shares of Kenvue in a research note on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.17.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.